Á lódáil...
The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN
The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis share driver mutations that either activate the thrombopoietin receptor, MPL, or indirectly activate it through mutations in the gene for JAK2, its cognate tyrosine kinase. Paradoxically, although...
Na minha lista:
| Foilsithe in: | Front Oncol |
|---|---|
| Main Authors: | , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Frontiers Media S.A.
2021
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7987816/ https://ncbi.nlm.nih.gov/pubmed/33777803 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.641613 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|